Agache I, Beltran J, Akdis C, et al. - Researchers conducted systematic reviews to determine the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared with standard of care for severe eosinophilic asthma. Searching Pubmed, EMBASE and Cochrane Library they identified 19 RCTs for inclusion; 3 RCTs for benralizumab, 3 RCTs for dupilumab, 3 RCTs for mepolizumab, 4 RCTs for omalizumab, and 5 RCTs for reslizumab. These RCTs included individuals 12 to 75 years old (except for omalizumab including also individuals 6-11 years old), ranging from 12 to 56 weeks. These RCTs yielded evidence revealing that all approved biologicals lessen the rate of severe asthma exacerbations with high certainty and for benralizumab, dupilumab and mepolizumab for reducing oral corticosteroids. They identified moderate certainty for improving asthma control, QoL, FEV₁, and cost-effectiveness.